Skip to content
OpenCapital
Get started

Johnson & Johnson JNJ MEDTECH — Research and development expense

Other segment segments

Innovative Medicine
$2.81B+10.4%

Similar metrics at other companies

Knowles logo
KNMedTech & Specialty Audio — Adjusted Research and Development Expenses
$5M+11.1%
Baxter International logo
BAXHealthcare Systems & Technologies — Research and development expenses
$49M+8.9%
Baxter International logo
BAXMedical Products & Therapies — Research and development expenses
$54M-8.5%
Becton, Dickinson and Company logo
BDXMedical — Research and development expense
$130.75M+17.0%
Neuronetics logo
STIMMedical Device — Research And Development Expense
$1.31M-16.6%
Stryker logo
SYKMedSurg and Neurotechnology: — Research, development and engineering expenses
$231M+11.1%

Other financials

Income statement

See full
Revenue$24.1B+9.9%
Gross profit$16.0B+9.8%
Operating income$6.3B+2.3%
Net income$5.2B-52.4%
EPS (diluted)$2.14-52.9%

Balance sheet

See full
Cash & equivalents$21.7B-43.6%
Total debt$55.0B+5.2%
Total equity$81.2B+3.9%
Total assets$200.89B+3.7%

Cash flow

See full
Operating cash flow$2.5B-39.8%
CapEx$1.0B+31.9%
Free cash flow$1.5B-56.6%

Valuation

See full
Market cap$623.71B+66.9%
Enterprise value$657.01B+61.9%
P/E29.6×+13.2×
P/S6.5×+2.3×

Profitability

See full
Gross margin67.8%-0.5pp
Operating margin26.4%+2.8pp
Net margin21.8%-2.6pp
FCF margin18.5%-4.3pp

Returns & leverage

See full
Return on equity26.4%-3.0pp
Debt / equity0.7×0.0×
Current ratio1×-0.2×

Where this comes from

Reported directly by Johnson & Johnson in its filing.

Tagged under the XBRL concept us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost.

The official record: Johnson & Johnson’s 10-Q, filed April 22, 2026, on SEC EDGAR. View the filing →

Ask your AI about Johnson & Johnson's medtech — research and development expense.

Connect your AI assistant and compare segments, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Johnson & Johnson's MEDTECH — research and development expense?
Johnson & Johnson (JNJ) reported MEDTECH — research and development expense of $714M in Q1 2026.
How has Johnson & Johnson's MEDTECH — research and development expense changed year-over-year?
Johnson & Johnson's MEDTECH — research and development expense increased by 5.5% year-over-year, from $677M to $714M.
What is the long-term trend for Johnson & Johnson's MEDTECH — research and development expense?
Over 3 years (2022 to 2025), Johnson & Johnson's MEDTECH — research and development expense has grown at a 4.4% compound annual growth rate (CAGR), from $2.49B to $2.84B.
What does MEDTECH — research and development expense mean?
Captures the investment in innovation, clinical trials, and product development within the MedTech segment. This reflects the company's commitment to future product pipelines and technological advancement in medical devices.